VERTEX PHARMACEUTICALS INC / MA — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Owns After | Date |
|---|---|---|---|---|---|---|---|
| Sachdev Amit | EVP, Chief Patient Officer | Award / Grant | 7,866 | — | — | 79,752 | May 17, 2022 |
| Arbuckle Stuart A | EVP, COO | Sale | 10 | $247.95 | $2,480 | 64,872 | May 16, 2022 |
| Sanna Bastiano | EVP, Cell & Genetic Therapies | Sale | 8 | $254.44 | $2,036 | 41,749 | May 16, 2022 |
| Liu Joy | SVP, General Counsel | Sale | 34 | $253.87 | $8,632 | 14,369 | May 16, 2022 |
| Sanna Bastiano | EVP, Cell & Genetic Therapies | Sale | 36 | $275.09 | $9,903 | 41,660 | May 4, 2022 |
| Arbuckle Stuart A | EVP, COO | Sale | 306 | $263.98 | $80,778 | 64,760 | May 2, 2022 |
| Sanna Bastiano | EVP, Cell & Genetic Therapies | Sale | 43 | $258.46 | $11,114 | 41,863 | May 2, 2022 |
| Bhatia Sangeeta N. | — | Sale | 280 | $257.51 | $72,103 | 6,320 | May 2, 2022 |
| WAGNER CHARLES F JR | EVP & Chief Financial Officer | Sale | 100 | $257.18 | $25,718 | 42,953 | May 2, 2022 |
| Kearney Terrence C | — | Award / Grant | 725 | — | — | 6,536 | May 1, 2022 |
| MCKENZIE DIANA | — | Disposition | 1,842 | — | — | 1,435 | May 1, 2022 |
| Bhatia Sangeeta N. | — | Award / Grant | 1,449 | — | — | 6,640 | May 1, 2022 |
| MCGLYNN MARGARET G | — | Disposition | 921 | — | — | 178 | May 1, 2022 |
| CARNEY LLOYD | — | Award / Grant | 1,449 | — | — | 6,850 | May 1, 2022 |
| Liu Joy | SVP, General Counsel | Sale | 22 | $276.72 | $6,088 | 14,344 | Apr 29, 2022 |
| WAGNER CHARLES F JR | EVP & Chief Financial Officer | Tax Withholding | 547 | $276.17 | $151,065 | 43,073 | Apr 29, 2022 |
| Sanna Bastiano | EVP, Cell & Genetic Therapies | Tax Withholding | 766 | $276.17 | $211,546 | 42,016 | Apr 29, 2022 |
| Ambrose Kristen | SVP & Chief Accounting Officer | Sale | 83 | $269.51 | $22,369 | 3,600 | Apr 25, 2022 |
| Lee Yuchun | — | Sale | 382 | $282.70 | $107,991 | 3,493 | Apr 18, 2022 |
| Lee Yuchun | — | Sale | 252 | $288.92 | $72,808 | 2,675 | Apr 14, 2022 |
| LEIDEN JEFFREY M | Executive Chairman | Sale | 15,789 | $289.04 | $4,563,653 | 74,160 | Apr 13, 2022 |
| Lee Yuchun | — | Sale | 300 | $286.24 | $85,872 | 3,029 | Apr 13, 2022 |
| Lee Yuchun | — | Sale | 430 | $277.29 | $119,235 | 3,027 | Apr 8, 2022 |
| Bhatia Sangeeta N. | — | Option Exercise | 1,907 | $125.71 | $239,729 | 7,098 | Apr 8, 2022 |
| MCGLYNN MARGARET G | — | Option Exercise | 5,000 | $127.54 | $637,700 | 6,099 | Apr 8, 2022 |
| Lee Yuchun | — | Sale | 17 | $267.57 | $4,549 | 3,858 | Apr 7, 2022 |
| Sanna Bastiano | EVP, Cell & Genetic Therapies | Sale | 30 | $277.02 | $8,311 | 42,782 | Apr 7, 2022 |
| Sanna Bastiano | EVP, Cell & Genetic Therapies | Sale | 305 | $267.10 | $81,466 | 46,763 | Apr 5, 2022 |
| Lee Yuchun | — | Option Exercise | 2,000 | $81.54 | $163,080 | 3,875 | Apr 4, 2022 |
| Ambrose Kristen | SVP & Chief Accounting Officer | Tax Withholding | 137 | $263.09 | $36,043 | 3,823 | Apr 1, 2022 |
| WAGNER CHARLES F JR | EVP & Chief Financial Officer | Sale | 536 | $265.95 | $142,549 | 43,843 | Apr 1, 2022 |
| Sanna Bastiano | EVP, Cell & Genetic Therapies | Tax Withholding | 1,344 | $263.09 | $353,593 | 47,068 | Apr 1, 2022 |
| MCGLYNN MARGARET G | — | Sale | 1,019 | $261.28 | $266,244 | 5,080 | Mar 31, 2022 |
| Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Sale | 2,799 | $250.10 | $700,030 | 47,390 | Mar 17, 2022 |
| WAGNER CHARLES F JR | EVP & Chief Financial Officer | Sale | 3,110 | $250.13 | $777,904 | 46,263 | Mar 17, 2022 |
| Sanna Bastiano | EVP, Cell & Genetic Therapies | Sale | 2,122 | $250.06 | $530,627 | 48,412 | Mar 17, 2022 |
| Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Sale | 115 | $230.97 | $26,562 | 50,294 | Feb 25, 2022 |
| WAGNER CHARLES F JR | EVP & Chief Financial Officer | Tax Withholding | 2,189 | $227.86 | $498,786 | 49,373 | Feb 24, 2022 |
| Sachdev Amit | EVP, Chief Patient Officer | Tax Withholding | 7,368 | $227.86 | $1,678,872 | 48,210 | Feb 24, 2022 |
| Liu Joy | SVP, General Counsel | Tax Withholding | 1,554 | $227.86 | $354,094 | 14,454 | Feb 24, 2022 |
| LEIDEN JEFFREY M | Executive Chairman | Tax Withholding | 12,141 | $227.86 | $2,766,448 | 89,949 | Feb 24, 2022 |
| Kewalramani Reshma | CEO & President | Tax Withholding | 7,246 | $227.86 | $1,651,074 | 122,842 | Feb 24, 2022 |
| Bozic Carmen | EVP and CMO | Tax Withholding | 1,242 | $227.86 | $283,002 | 49,823 | Feb 24, 2022 |
| Arbuckle Stuart A | EVP, COO | Tax Withholding | 7,246 | $227.86 | $1,651,074 | 65,066 | Feb 24, 2022 |
| ALTSHULER DAVID | EVP, Global Research and CSO | Sale | 1,040 | $229.41 | $238,586 | 42,609 | Feb 24, 2022 |
| Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Sale | 101 | $230.42 | $23,272 | 53,304 | Feb 18, 2022 |
| WAGNER CHARLES F JR | EVP & Chief Financial Officer | Tax Withholding | 3,439 | $232.51 | $799,602 | 51,562 | Feb 17, 2022 |
| Sanna Bastiano | EVP, Cell & Genetic Therapies | Tax Withholding | 3,439 | $232.51 | $799,602 | 50,534 | Feb 17, 2022 |
| Sachdev Amit | EVP, Chief Patient Officer | Tax Withholding | 3,497 | $232.51 | $813,087 | 55,578 | Feb 17, 2022 |
| Liu Joy | SVP, General Counsel | Tax Withholding | 712 | $232.51 | $165,547 | 16,008 | Feb 17, 2022 |